- Home
- RENB
as 07-26-2024 4:00pm EST
Renovaro Inc formerly Renovaro Biosciences Inc is a biopharmaceutical company. It is engaged in the research and development of pharmaceutical and biological products for the treatment of HIV, HBV, and cancer with the intent to manufacture said products.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | SUITE 906 LOS ANGELES |
| Market Cap: | 136.1M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 610.1K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.57 - $5.25 | Next Earning Date: | 05-15-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Renovaro Biosciences Inc. (RENB)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| William Anderson Wittekind | RENB | 10% Owner | Jul 15 '24 | Sell | $1.41 | 21,954 | $30,955.14 | 875,795 | SEC Form 4 |
| William Anderson Wittekind | RENB | 10% Owner | Jul 3 '24 | Sell | $1.55 | 60,000 | $93,000.00 | 974,275 | SEC Form 4 |
| William Anderson Wittekind | RENB | 10% Owner | Jul 3 '24 | Sell | $1.51 | 50,000 | $75,500.00 | 1,034,275 | SEC Form 4 |
| William Anderson Wittekind | RENB | 10% Owner | Jul 1 '24 | Sell | $1.54 | 34,553 | $53,211.62 | 1,084,275 | SEC Form 4 |
| William Anderson Wittekind | RENB | 10% Owner | Jul 1 '24 | Sell | $1.56 | 60,000 | $93,600.00 | 1,118,828 | SEC Form 4 |
| William Anderson Wittekind | RENB | 10% Owner | Jun 25 '24 | Sell | $1.50 | 14,671 | $22,006.50 | 1,178,828 | SEC Form 4 |
| William Anderson Wittekind | RENB | 10% Owner | Jun 25 '24 | Sell | $1.57 | 50,000 | $78,500.00 | 1,193,499 | SEC Form 4 |
| William Anderson Wittekind | RENB | 10% Owner | Jun 25 '24 | Sell | $1.58 | 20,000 | $31,600.00 | 1,243,499 | SEC Form 4 |
| William Anderson Wittekind | RENB | 10% Owner | Jun 14 '24 | Sell | $1.58 | 50,000 | $79,000.00 | 1,263,499 | SEC Form 4 |
Latest Renovaro Biosciences Inc. News
RENB Breaking Stock News: Dive into RENB Ticker-Specific Updates for Smart Investing
The Wall Street Journal
15 hours ago
The Junk in Your Index Fund Is Costing You Big-Time
GlobeNewswire
a month ago
Renovaro, Inc. Announces $10 million in Equity Committed
GlobeNewswire
2 months ago
Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy
GlobeNewswire
3 months ago
Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics
GlobeNewswire
3 months ago
RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership
GlobeNewswire
3 months ago
Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient Care
GlobeNewswire
5 months ago
Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace
GlobeNewswire
5 months ago
Statement of Renovaro Inc
Compare RENB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RENB Renovaro Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.